By Saloni Sinha ( July 20, 2026, 06:30 GMT | Insight) -- Zoetis’ proposed acquisition of Neogen’s Genomics Business would not raise competition concerns in Australia, the company said after the country’s antitrust regulator announced the deal would require an in-depth Phase 2 review under the new mandatory, suspensory merger regime. In a statement to MLex on Monday, Zoetis said it would continue to work “cooperatively” with the Australian Competition & Consumer Commission, after the regulator said the proposed acquisition would combine the two largest suppliers of genomic-testing services for cattle in the country and could substantially lessen competition in certain markets.Zoetis’ proposed acquisition of Neogen’s Genomics Business would not raise competition concerns in Australia, the company said after the country’s antitrust regulator announced the deal would require an in-depth Phase 2 review under the new mandatory, suspensory merger regime....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.